
Orforglipron (Foundayo)
Orforglipron (Foundayo) is an FDA-approved once-daily GLP-1 receptor agonist pill for chronic weight management. In two 72-week placebo-controlled trials, the highest dose lowered body weight by about 11% in adults without diabetes and about 10% in adults with type 2 diabetes, compared with about 2% on placebo, and a 52-week trial found it helped people keep off much of the weight they had lost on tirzepatide or semaglutide injections. Stomach and bowel side effects are common, and the label carries a boxed warning about thyroid C-cell tumors.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with obesity, or overweight plus a weight-related condition, whose prescriber recommends a daily oral GLP-1 medicine alongside diet and activity changes
Common dosing range
Set by your prescriber. The label starts at 0.8 mg once daily and steps up at least every 30 days (2.5 mg, then 5.5 mg, and if needed 9 mg, 14.5 mg or 17.2 mg once daily)
When to expect effects
Weight loss builds over months; in the trials, the main result was measured after 72 weeks
Watch out for
Boxed warning: thyroid C-cell tumors were seen in rodents with other GLP-1 drugs, and it must not be used with a personal or family history of medullary thyroid cancer or MEN 2. Nausea, vomiting, diarrhea and constipation are common. It can affect pancreas, gallbladder and kidneys, may cause fetal harm, and can make birth control pills less reliable for 30 days after starting and after each dose increase
What is it
Orforglipron is a prescription weight-management medicine sold as Foundayo tablets by Eli Lilly. The FDA approved it on April 1, 2026 as a new molecular entity (NDA 220934), and the FDA approved an updated label on August 4, 2026. It is a GLP-1 receptor agonist, the same drug class as semaglutide and liraglutide, but it is a small molecule taken by mouth once a day rather than an injected peptide. The Foundayo label approves it, together with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off long term in adults with obesity, or adults with overweight and at least one weight-related condition. It is not approved for children, and the label says use together with another GLP-1 receptor agonist is not recommended.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
weight loss in adults with obesity without diabetes Good Evidence | About 9 percentage points more weight loss than placebo at the highest dose | Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes | Measured at 72 weeks |
weight loss in adults with obesity and type 2 diabetes Good Evidence | About 7 percentage points more weight loss than placebo at the highest dose | Adults with type 2 diabetes and overweight or obesity treated with diet or oral diabetes medicines | Measured at 72 weeks |
keeping weight off after stopping tirzepatide or semaglutide injections Good Evidence | About 25 to 42 percentage points more of the lost weight kept than with placebo | Adults who lost weight on tirzepatide or semaglutide injections, the only groups this trial studied | Measured at 52 weeks |
weight loss in adults with obesity without diabetes
- Effect
- About 9 percentage points more weight loss than placebo at the highest dose
- Best fit
- Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes
- Time
- Measured at 72 weeks
weight loss in adults with obesity and type 2 diabetes
- Effect
- About 7 percentage points more weight loss than placebo at the highest dose
- Best fit
- Adults with type 2 diabetes and overweight or obesity treated with diet or oral diabetes medicines
- Time
- Measured at 72 weeks
keeping weight off after stopping tirzepatide or semaglutide injections
- Effect
- About 25 to 42 percentage points more of the lost weight kept than with placebo
- Best fit
- Adults who lost weight on tirzepatide or semaglutide injections, the only groups this trial studied
- Time
- Measured at 52 weeks
Evidence for 3 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
weight loss in adults with obesity without diabetes
Disease adjunctIn the double-blind ATTAIN-1 trial, 3,127 adults with obesity (or overweight with a weight-related condition) and no diabetes took orforglipron 6, 12 or 36 mg or placebo once daily for 72 weeks, with diet and activity counseling. Body weight fell by 7.5%, 8.4% and 11.2% on the three doses versus 2.1% on placebo. On the highest dose, 54.6% lost at least 10% of their weight, 36.0% at least 15% and 18.4% at least 20%, compared with 12.9%, 5.9% and 2.8% on placebo. Waist size, systolic blood pressure, triglycerides and non-HDL cholesterol also improved. Side effects led 5.3% to 10.3% to stop, versus 2.7% on placebo. The trial used an investigational formulation; the Foundayo label presents its results as the equivalent Foundayo doses of 5.5, 9 and 17.2 mg. The trial was funded by the manufacturer.
Bottom line: Daily orforglipron with lifestyle changes led to about 11% weight loss at the top dose over 72 weeks, versus about 2% on placebo.
weight loss in adults with obesity and type 2 diabetes
Disease adjunctIn the double-blind ATTAIN-2 trial, 1,613 adults with a BMI of 27 or more and type 2 diabetes (HbA1c 7% to 10%, average 8.05%) took orforglipron 6, 12 or 36 mg or placebo once daily for 72 weeks. Body weight fell by 5.1%, 7.0% and 9.6% versus 2.5% on placebo, and HbA1c and other heart and metabolic measures also improved. Stopping because of side effects, mainly stomach-related, was 6.1% to 9.9% on orforglipron versus 4.1% on placebo. People on insulin or other injectable diabetes drugs were excluded. As in ATTAIN-1, the Foundayo label presents these doses of the investigational formulation as 5.5, 9 and 17.2 mg of Foundayo. The trial was funded by the manufacturer.
Bottom line: In people with type 2 diabetes, orforglipron led to about 10% weight loss at the top dose over 72 weeks, versus about 2.5% on placebo.
keeping weight off after stopping tirzepatide or semaglutide injections
Disease adjunctThe double-blind ATTAIN-MAINTAIN trial enrolled 376 adults who had already lost weight on tirzepatide (205 people) or semaglutide (171 people) in an earlier study, then switched them to daily orforglipron or placebo for 52 weeks. Among those whose weight had plateaued, people coming from tirzepatide kept an estimated 74.7% of their weight loss on orforglipron versus 49.2% on placebo, and people coming from semaglutide kept 79.3% versus 37.6%. The authors note there was no group that simply stayed on the injection, and the trial lasted only one year. It was funded by the manufacturer.
Bottom line: In people who had lost weight on tirzepatide or semaglutide, orforglipron kept much more of the lost weight off than placebo over one year; it was not compared with staying on the injection.
How it works
How to take it
What to track
Bottom line: One tablet a day, with or without food, stepped up slowly by your prescriber; tell every prescriber and surgeon you take it.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Risk of thyroid C-cell tumors (boxed warning). Other GLP-1 drugs caused thyroid C-cell tumors in rats and mice. Orforglipron is not active in rats or mice and caused no tumors there, but whether such tumors matter for humans has not been determined. It is contraindicated with a personal or family history of medullary thyroid cancer or with MEN 2.
Acute pancreatitis. In the two main trials, 6 people on orforglipron and 1 on placebo had confirmed acute pancreatitis. The label says to stop it if pancreatitis is suspected.
Severe stomach and bowel reactions (about 3% versus 1% on placebo) and acute kidney injury from dehydration after vomiting or diarrhea. It is not recommended in severe gastroparesis.
Low blood sugar, especially with insulin or a sulfonylurea; gallbladder disease such as gallstones; serious allergic reactions; worsening diabetic eye disease with fast glucose improvement; and food remaining in the stomach during anesthesia or deep sedation, which can lead to pulmonary aspiration.
Who should avoid it
- People with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2 (contraindicated)
- People with a known serious allergy to orforglipron or any tablet ingredient (contraindicated)
- People with severe gastroparesis or severe liver impairment (Child-Pugh C), where it is not recommended, and anyone already taking another GLP-1 receptor agonist
- Children and teenagers, in whom safety and effectiveness have not been established
Pregnancy & breastfeeding
Pregnancy: the Foundayo label says it may cause fetal harm, that weight loss offers no benefit during pregnancy, and that it should be stopped when pregnancy is recognized. There are no adequate studies in pregnant women. In a rabbit dose-finding study, exposures 14 times the human exposure at the highest dose caused external malformations in 2 fetuses, while the main rabbit study, at up to about 6 times that exposure, found no effects on the fetus. The label advises effective contraception, and because the drug slows stomach emptying, people using birth control pills should switch to a non-oral method or add a barrier method for 30 days after starting and for 30 days after each dose increase. A pregnancy registry is planned. Breastfeeding: there are no data on orforglipron in human milk; it passed into rat milk at levels 3 times higher than in blood, and the label says it is not recommended while nursing.
Interactions
Orforglipron slows stomach emptying, which can change how other tablets are absorbed. The label tells people on oral hormonal birth control to switch to a non-oral method or add a barrier method for 30 days after starting and after each dose increase. Birth control that is not taken by mouth is not expected to be affected.
These raise orforglipron levels and side-effect risk. The label caps the dose at 9 mg a day with a strong CYP3A4 blocker and says to avoid those that also block the OATP1B transporter, such as ritonavir. Make sure every prescriber knows you take Foundayo.
The Foundayo label says to avoid strong CYP3A4 inducers with Foundayo, because they lower orforglipron levels, which may make it work less well. In a study, the strong inducer carbamazepine cut orforglipron exposure by 82%. Your prescriber decides whether a change is needed, so talk to them before stopping or changing either medicine.
The Foundayo label says to avoid strong CYP3A4 inducers because they lower orforglipron levels and may make it work less well (the strong inducer carbamazepine cut exposure by 82%). The FDA classes St. John's wort as a strong CYP3A inducer, although its effect varies by product. It has not been tested with orforglipron. Avoid it unless your prescriber agrees, and talk to your prescriber or pharmacist before changing either one.
Together they raise the risk of low blood sugar, including severe episodes. In a trial of people with type 2 diabetes, 7% of those also taking a sulfonylurea had low blood sugar, versus 0.5% of those who were not. The label says a lower dose of insulin or sulfonylurea may be needed; your prescriber decides.
These also lower orforglipron levels: a computer model on the label predicted a 61% drop in exposure with efavirenz. With moderate inducers, the label says to monitor how well Foundayo works and step up the dose as needed. Your prescriber decides whether a change is needed.
Orforglipron doubled exposure to the active form of simvastatin in a study. The label says not to exceed simvastatin 20 mg once daily together with Foundayo. Ask your prescriber or pharmacist to review your statin dose.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is orforglipron FDA-approved?⌄
Yes. The FDA approved orforglipron as Foundayo tablets on April 1, 2026, for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, together with diet and physical activity. It is a prescription medicine. It is not approved for children, and its label is for weight management, not as a diabetes treatment.
How is it different from semaglutide or tirzepatide injections?⌄
Orforglipron works on the same GLP-1 receptor as semaglutide, but it is a small-molecule tablet taken once a day, with or without food, instead of a weekly injection. In the trials behind the Foundayo label, orforglipron was compared with placebo, not head to head with these injections, so the trials do not show which works better for weight.
Can I take my supplements with orforglipron?⌄
Our interaction database has no supplement pairs for orforglipron yet, and we found no study that tested supplements with it. Because it slows stomach emptying and is broken down by the enzyme CYP3A4, ask your doctor or pharmacist to check every supplement and medicine you take, especially herbal products.
Does it affect birth control pills?⌄
It can. The label says to switch to a non-oral birth control method, or add a barrier method such as condoms, for 30 days after starting Foundayo and for 30 days after each dose increase. Birth control that is not taken by mouth is not expected to be affected. The label also says to stop it if pregnancy is recognized.
What are the most common side effects?⌄
Nausea, constipation, diarrhea, vomiting, indigestion and belly pain were the most common in the trials, mostly mild to moderate and most frequent while the dose was being increased. About 8% of people on it stopped because of side effects, versus 3% on placebo. Severe or lasting stomach pain needs prompt medical attention.
Is it safe to buy orforglipron online?⌄
Foundayo is a prescription medicine dispensed by licensed pharmacies. Products sold online as orforglipron without a prescription, including "research" products, are not FDA-approved Foundayo, and their content and purity are unverified. Talk to your doctor about whether it fits you.
References by claim
weight loss in adults with obesity without diabetes
Wharton et al., 2025 · PubMed (2025) link
weight loss in adults with obesity and type 2 diabetes
Horn et al., 2026 · PubMed (2026) link
keeping weight off after stopping tirzepatide or semaglutide injections
Aronne et al., 2026 · PMC (2026) link
Safety
Foundayo (orforglipron) prescribing information · DailyMed (FDA label) link
Track Orforglipron (Foundayo) with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
